Cargando…

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma

BACKGROUND: New effective treatments for metastatic melanoma greatly improve survival in a proportion of patients. However biomarkers to identify patients that are more likely to benefit from a particular treatment are needed. We previously reported on a multimarker approach for the detection of het...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klinac, Dragana, Gray, Elin S, Freeman, James B, Reid, Anna, Bowyer, Samantha, Millward, Michael, Ziman, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060872/ https://www.ncbi.nlm.nih.gov/pubmed/24915896 http://dx.doi.org/10.1186/1471-2407-14-423

Ejemplares similares

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells
por: Freeman, James B, et al.
Publicado: (2012)

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment
por: Gray, Elin S, et al.
Publicado: (2015)

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles
por: Aya-Bonilla, Carlos, et al.
Publicado: (2019)

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
por: Warburton, Lydia, et al.
Publicado: (2020)

Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device
por: Aya-Bonilla, Carlos A., et al.
Publicado: (2017)

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
por: Gray, Elin S., et al.
Publicado: (2015)

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
por: Aya-Bonilla, Carlos Alberto, et al.
Publicado: (2020)

Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies
por: McEvoy, Ashleigh C., et al.
Publicado: (2019)

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
por: Calapre, Leslie, et al.
Publicado: (2018)

Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma
por: Beasley, Aaron, et al.
Publicado: (2018)

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection
por: Marsavela, Gabriela, et al.
Publicado: (2020)

Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
por: Calapre, Leslie, et al.
Publicado: (2019)

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2019)

Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture
por: Beasley, Aaron B., et al.
Publicado: (2021)

Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients
por: Acheampong, Emmanuel, et al.
Publicado: (2022)

Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma
por: Dunkel, Ying, et al.
Publicado: (2018)

Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer
por: Acheampong, Emmanuel, et al.
Publicado: (2022)

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2020)

Detection of metastases using circulating tumour DNA in uveal melanoma
por: Beasley, Aaron B., et al.
Publicado: (2023)

Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
por: Marsavela, Gabriela, et al.
Publicado: (2021)

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Acheampong, Emmanuel, et al.
Publicado: (2020)

A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision
por: Stark, Mitchell S., et al.
Publicado: (2019)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
por: Acheampong, Emmanuel, et al.
Publicado: (2019)

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
por: McEvoy, Ashleigh C., et al.
Publicado: (2017)

Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients
por: Asante, Du-Bois, et al.
Publicado: (2023)

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
por: Asante, Du-Bois, et al.
Publicado: (2021)

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
por: Warburton, L., et al.
Publicado: (2020)

Circulating Tumour DNA in Melanoma—Clinic Ready?
por: Tivey, Ann, et al.
Publicado: (2022)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

The immune cell landscape of metastatic uveal melanoma correlates with overall survival
por: Tosi, Anna, et al.
Publicado: (2021)

Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma
por: Woof, Victoria G., et al.
Publicado: (2022)

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
por: Navani, Vishal, et al.
Publicado: (2021)

A diagnostic autoantibody signature for primary cutaneous melanoma
por: Zaenker, Pauline, et al.
Publicado: (2018)

Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients
por: Long-Mira, Elodie, et al.
Publicado: (2018)

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
por: Clark, Michael E., et al.
Publicado: (2020)

Landscape of circulating tumour DNA in metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o7lsd8psgs1s3n7oj7r8pel2mo